A cross-national perspective on cost of illness

Polder, J.J.; Meerding, Willem Jan; Bonneux, Luc; Maas, P.J. van der

doi:10.1007/s10198-005-0295-0

Cited by 17 publications

(7 citation statements)

References 11 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since studies investigating the cost of pre-dialyses CKD are heterogeneous in terms of stage of disease analyzed, methods, perspective of analysis, target population and country, comparisons between study results have to be made with caution [40]. However, a different burden of hospitalization costs on the total direct medical costs have been found in our study with respect to other studies.…”

Section: Discussionmentioning

confidence: 69%

The social cost of chronic kidney disease in Italy

et al. 2016

View full text Add to dashboard Cite

This study aims to estimate the mean annual social cost per patient with chronic kidney disease (CKD) by stages 4 and 5 pre-dialyses and cost components in Italy. The multicenter cross-sectional study included all adult outpatients in charge of the 14 main Nephrology Centers of Tuscany Region during 7 weeks from 2012 to 2013. Direct medical costs have been estimated using tariffs for laboratory tests, diagnostic exams, visits, hospitalization and prices for drugs. Non-medical costs included expenses of low-protein special foods, travel, and formal and informal care. Patients’ and caregivers’ losses of productivity have been estimated as indirect costs using the human capital approach. Costs have been expressed in Euros (2016). Totals of 279 patients in stage 4 and 205 patients in stage 5 have been enrolled. The estimated mean annual social cost of a patient with CKD were €7422 (±€6255) for stage 4 and €8971 (±€6503) for stage 5 (p < 0.05). Direct medical costs were higher in stage 5 as compared to stage 4; direct non-medical costs and indirect costs accounted, respectively, for 41 and 5 % of the total social cost of CKD stage 4 and for 33 and 9 % of CKD stage 5. In Italy, the overall annual social cost of CKD was €1,809,552,398 representing 0.11 % of the Gross Domestic Product. Direct non-medical costs and indirect costs were weighted on the social cost of CKD almost as much as the direct medical cost. Patients, their families and the productivity system sustain the burden of the disease almost as much as the healthcare system.Electronic supplementary materialThe online version of this article (doi:10.1007/s10198-016-0830-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 69%

The social cost of chronic kidney disease in Italy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The effect of physical comorbidities in cost-of-illness studies has been widely debated [ 61 , 62 ]. Failing to control for comorbidities leads to obtaining increased incremental cost of the investigated disease and causes double-counting of costs [ 62 , 63 ]. However, adjusting for comorbidities that are caused by the disease of interest would lead to underestimation of the cost estimates associated with the disease [ 61 ].…”

Section: Discussionmentioning

confidence: 99%

The excess economic burden of mental disorders: findings from a cross-sectional prevalence survey in Austria

et al. 2020

View full text Add to dashboard Cite

Information about the scope of mental disorders (MDs), resource use patterns in health and social care sectors and economic cost is crucial for adequate mental healthcare planning. This study provides the first representative estimates about the overall utilisation of resources by people with MDs and the excess healthcare and productivity loss costs associated with MDs in Austria. Data were collected in a cross-sectional survey conducted on a representative sample ( n = 1008) between June 2015 and June 2016. Information on mental health diagnoses, 12-month health and social care use, medication use, comorbidities, informal care, early retirement, sick leave and unemployment was collected via face-to-face interviews. Generalised linear model was used to assess the excess cost of MDs. The healthcare cost was 37% higher ( p = 0.06) and the total cost was twice as high ( p < 0.001) for the respondents with MDs compared to those without MDs. Lost productivity cost was over 2.5-times higher ( p < 0.001) for those with MDs. Participants with severe MDs had over 2.5-times higher health and social care cost ( p < 0.001) and 9-times higher mental health services cost ( p < 0.001), compared to those with non-severe MDs. The presence of two or more physical comorbidities was a statistically significant determinant of the total cost. Findings suggest that the overall excess economic burden on health and social care depends on the severity of MDs and the number of comorbidities. Both non-severe and severe MDs contribute to substantially higher loss productivity costs compared to no MDs. Future resource allocation and service planning should take this into consideration.

show abstract

“…Cost of illness (COI) data from The Netherlands for 2003 were used to estimate health-care expenditure for the different cohorts [ 28 ]. The 2003 COI study was a sequel to earlier COI 1999 studies in the Netherlands [ 29 – 31 ] and COI estimates were made using the health-care cost definitions of the System of Health Accounts (SHA) for reasons of international comparability of costs [ 32 ]. Average annual costs per patient having a certain disease were calculated by dividing total annual costs by Dutch prevalence numbers for each disease in 2003.…”

Section: Methodsmentioning

confidence: 99%

Lifetime Medical Costs of Obesity: Prevention No Cure for Increasing Health Expenditure

et al. 2008

View full text Add to dashboard Cite

BackgroundObesity is a major cause of morbidity and mortality and is associated with high medical expenditures. It has been suggested that obesity prevention could result in cost savings. The objective of this study was to estimate the annual and lifetime medical costs attributable to obesity, to compare those to similar costs attributable to smoking, and to discuss the implications for prevention.Methods and FindingsWith a simulation model, lifetime health-care costs were estimated for a cohort of obese people aged 20 y at baseline. To assess the impact of obesity, comparisons were made with similar cohorts of smokers and “healthy-living” persons (defined as nonsmokers with a body mass index between 18.5 and 25). Except for relative risk values, all input parameters of the simulation model were based on data from The Netherlands. In sensitivity analyses the effects of epidemiologic parameters and cost definitions were assessed. Until age 56 y, annual health expenditure was highest for obese people. At older ages, smokers incurred higher costs. Because of differences in life expectancy, however, lifetime health expenditure was highest among healthy-living people and lowest for smokers. Obese individuals held an intermediate position. Alternative values of epidemiologic parameters and cost definitions did not alter these conclusions.ConclusionsAlthough effective obesity prevention leads to a decrease in costs of obesity-related diseases, this decrease is offset by cost increases due to diseases unrelated to obesity in life-years gained. Obesity prevention may be an important and cost-effective way of improving public health, but it is not a cure for increasing health expenditures.

show abstract

A cross-national perspective on cost of illness

Cited by 17 publications

References 11 publications

The social cost of chronic kidney disease in Italy

The social cost of chronic kidney disease in Italy

The excess economic burden of mental disorders: findings from a cross-sectional prevalence survey in Austria

Lifetime Medical Costs of Obesity: Prevention No Cure for Increasing Health Expenditure

Contact Info

Product

Resources

About